The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Open accessAbstract
OBJECTIVE: The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-d-aspartate (NMDA) receptor antagonists in the treatment of major depression. METHOD: Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials of NMDA antagonists in the treatment of depression. Primary outcomes were rates of treatment response and transient remission of symptoms. Secondary outcomes included change in depression symptom severity and the frequency and severity of dissociative and psychotomimetic effects. Results for each NMDA antagonist were combined in meta-analyses, reporting odds ratios for dichotomous outcomes and standardized mean differences for continuous outcomes. RESULTS: Ketamine (seven trials encompassing 147 ketamine-treated participants) produced a rapid, yet transient, antidepressant effect, with odds ratios for response and transient remission of symptoms at 24 hours equaling 9.87 (4.37-22.29) and 14.47 (2.67-78.49), respectively, accompanied by brief psychotomimetic and dissociative effects. Ketamine augmentation of ECT (five trials encompassing 89 ketamine-treated participants) significantly reduced depressive symptoms following an initial treatment (Hedges' g=0.933) but not at the conclusion of the ECT course. Other NMDA antagonists failed to consistently demonstrate efficacy; however, two partial agonists at the NMDA coagonist site, d-cycloserine and rapastinel, significantly reduced depressive symptoms without psychotomimetic or dissociative effects. CONCLUSIONS: The antidepressant efficacy of ketamine, and perhaps D-cycloserine and rapastinel, holds promise for future glutamate-modulating strategies; however, the ineffectiveness of other NMDA antagonists suggests that any forthcoming advances will depend on improving our understanding of ketamine's mechanism of action. The fleeting nature of ketamine's therapeutic benefit, coupled with its potential for abuse and neurotoxicity, suggest that its use in the clinical setting warrants caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of note, however, rapastinel, another drug that reverses synaptic plasticity deficits and exhibits antidepressant-like effects in rodent models 36,37 , has been studied in 3 clinical trials to date with relatively weak evidence for its efficacy 38 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [38]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [8]
In the citing paper
“This is supported by the finding that other NMDA receptor antagonists such as memantine, lanicemine and nitrous oxide do not exert a consistent antidepressant effect in RCTs.90”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [90]
In the citing paper
“Ketamine's antidepressant effects compared to placebo controls are further supported by several thorough meta-analyses [134-136].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [134]
In the citing paper
“This literature leads to the conclusion that while alternative NMDAR channel-blocking antagonists may exert clinical antidepressant actions, such actions are not of the same time frame or magnitude as those exerted by ketamine.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
In the citing paper
“However, clinical trials indicate that these alternative NMDAR antagonists, lack the rapid, robust and/or long-lasting antidepressant actions of ketamine in humans 99.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 259
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,312
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Peters, J. L., Sutton, A. J., Jones, D. R., Abrams, K. R., & Rushton, L. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.010 · Cited by 2,053
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
Ketamine-Induced Neuronal Cell Death in the Perinatal Rhesus Monkey
Slikker, W., Zou, X., Hotchkiss, C. E., Divine, R. L., Sadovova, N., Twaddle, N. C., Doerge, D. R., Scallet, A. C., Patterson, T. A., Hanig, J. P., et al. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm084 · Cited by 612
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
Social Functioning in Depression: A Review
Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0405 · Cited by 586
Nierenberg, A. A., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 585
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Preskorn, S., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 524
Initiation and adaptation: a paradigm for understanding psychotropic drug action
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.2.151 · Cited by 490
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.027 · Cited by 454
Ketamine-induced Neuroapoptosis in the Fetal and Neonatal Rhesus Macaque Brain
Brambrink, A. M., Evers, A. S., Avidan, M. S., Farber, N. B., Smith, D. J., Martin, L. D., Dissen, G. A., Creeley, C. E., & Olney, J. W. (2012) · Anesthesiology · doi:10.1097/aln.0b013e318242b2cd · Cited by 427
Liu, R.-J., Lee, F. S., Li, X.-Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.09.030 · Cited by 403
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
D, M. F. M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M. M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.7.1161 · Cited by 367
Sackeïm, H. A., Prudic, J., Devanand, D. P., Decina, P., KERR, B., & Malitz, S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199004000-00004 · Cited by 361
McGrath, P. J., Stewart, J. W., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L. L., Biggs, M. M., Shores‐Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350
Multiple Mechanisms of Ketamine Blockade of N-methyl-D-aspartate Receptors
Orser, B. A., Pennefather, P., & MacDonald, J. F. (1997) · Anesthesiology · doi:10.1097/00000542-199704000-00021 · Cited by 346
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S. Z., Soleimani, L., Charney, D. S., Foulkes, A. L., & Mathew, S. J. (2014) · Depression and Anxiety · doi:10.1002/da.22253 · Cited by 345
d-Cycloserine: A ligand for the coupled glycine receptor has partial agonist characteristics
Hood, W. F., Compton, R. P., & Monahan, J. B. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90379-0 · Cited by 309
Ibrahim, L., DiazGranados, N., Franco-Chaves, J., Brutsche, N., Henter, I. D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D. A., Manji, H. K., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.338 · Cited by 309
Mathew, S. J., Murrough, J. W., Rot, M. A. H., Collins, K. A., Reich, D. L., & Charney, D. S. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 297
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277
Mg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
GOFF, D. C., Tsai, G. E., Manoach, D. S., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Gideons, E. S., Kavalali, E. T., & Monteggia, L. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323920111 · Cited by 232
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230
Belujon, P., & Grace, A. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.014 · Cited by 225
Shiroma, P. R., Johns, B., Kuskowski, M. A., Wels, J., THURAS, P. D., Albott, C. S., & Lim, K. O. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 222
Serial infusions of low-dose ketamine for major depression
Rasmussen, K. G., Lineberry, T. W., Galardy, C. W., Kung, S., Lapid, M. I., Palmer, B. A., Ritter, M. J., Schak, K. M., Sola, C. L., Hanson, A. J., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478283 · Cited by 221
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Ibrahim, L., DiazGranados, N., Jolkovsky, L., Brutsche, N., Luckenbaugh, D. A., Herring, W. J., Potter, W. Z., & Zarate, C. A. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d70d6 · Cited by 220
Salvadore, G., Cornwell, B. R., Sambataro, F., Latov, D. R., Colon-Rosario, V., Carver, F. W., Holroyd, T., Diazgranados, N., Machado‐Vieira, R., Grillon, C., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.24 · Cited by 220
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
Valentine, G. W., Mason, G. F., Gomez, R., Fasula, M. K., Watzl, J., Pittman, B. P., Krystal, J. H., & Sanacora, G. (2011) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2010.10.009 · Cited by 205
Naughton, M., Clarke, G. A., O’Leary, O. F., Cryan, J. F., & Dinan, T. G. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.11.014 · Cited by 195
PRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193
(2013) · PubMed · Cited by 192
Ibrahim, L. A., Diazgranados, N., Luckenbaugh, D. A., Machado‐Vieira, R., Baumann, J., Mallinger, A. G., & Zarate, C. A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.019 · Cited by 191
Organization, control and function of extrasynaptic NMDA receptors
Papouin, T., & Oliet, S. H. R. (2014) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2013.0601 · Cited by 189
Phelps, L. E., Brutsché, N. E., Moral, J. R., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.029 · Cited by 188
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
Yang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173
Watson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172
Ketamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172
Rogóż, Z., Skuza, G., Maj, J., & Danysz, W. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00055-2 · Cited by 169
Carlson, P. J., Diazgranados, N., Nugent, A. C., Ibrahim, L., Luckenbaugh, D. A., Brutsche, N., Herscovitch, P., Manji, H. K., Zarate, C. A., & Drevets, W. C. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.008 · Cited by 168
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Guevara, S., Machado-Vieira, R., Richards, E. M., Brutsche, N. E., Nolan, N. M., & Zarate, C. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08698 · Cited by 165
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Koike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 157
Wang, X., Chen, Y., Zhou, X., Liu, F., Zhang, T., & Zhang, C. (2012) · Journal of Ect · doi:10.1097/yct.0b013e31824d1d02 · Cited by 157
Potential Antidepressive Properties of Amantadine, Memantine and Bifemelane
Moryl, E., Danysz, W., & Quack, G. (1993) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1993.tb01351.x · Cited by 156
Machado-Vieira, R., Yuan, P., Brutsche, N., DiazGranados, N., Luckenbaugh, D., Manji, H. K., & Zarate, C. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04659 · Cited by 155
Saveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151
Continuation and Maintenance Electroconvulsive Therapy for Mood Disorders: Review of the Literature
Petrides, G., Tobias, K. G., Kellner, C. H., & Rudorfer, M. V. (2011) · Neuropsychobiology · doi:10.1159/000328943 · Cited by 151
Okamoto, N., Nakai, T., Sakamoto, K., Nagafusa, Y., Higuchi, T., & Nishikawa, T. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181c3b0aa · Cited by 150
Akinfiresoye, L. R., & Tizabi, Y. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3153-2 · Cited by 149
Petrakis, I. L., Limoncelli, D., Gueorguieva, R. V., Jatlow, P. L., Boutros, N. N., Trevisan, L. A., Gelernter, J. E., & Krystal, J. H. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1776 · Cited by 143
Subunit specificity and mechanism of action of NMDA partial agonist d-cycloserine
Sheinin, A., Shavit, S., & Benveniste, M. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00073-9 · Cited by 136
Moskal, J. R., Burch, R. M., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.852536 · Cited by 133
Ampuero, E., Rubio, F. J., Falcon, R., Sandoval, M., Diaz-Veliz, G., Gonzalez, R. E., Earle, N., Dagnino-Subiabre, A., Aboitiz, F., Orrego, F., et al. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.04.035 · Cited by 132
Kranaster, L., Kammerer-Ciernioch, J., Hoyer, C., & Sartorius, A. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0205-7 · Cited by 129
CYLOSERINE AS AN ANTIDEPRESSANT AGENT
CRANE, G. E. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.115.11.1025 · Cited by 127
Adams, B. W., & Moghaddam, B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01195-7 · Cited by 124
Rapid Antidepressant Effect of Ketamine in the Electroconvulsive Therapy Setting
Abdallah, C. G., Fasula, M. K., Kelmendi, B., Sanacora, G., & Ostroff, R. B. (2012) · Journal of Ect · doi:10.1097/yct.0b013e31824f8296 · Cited by 123
Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care
Irwin, S. A., & Iglewicz, A. (2010) · Journal of Palliative Medicine · doi:10.1089/jpm.2010.9808 · Cited by 123
Glutamate-Based Antidepressants: Preclinical Psychopharmacology
Pilc, A., Wierońska, J. M., & Skolnick, P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.021 · Cited by 119
Loo, C. K. A., Katalinic, N., Garfield, J. B. B., Sainsbury, K., Hadži-Pavlović, D., & MacPherson, R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.04.032 · Cited by 118
Yan, J., & Jiang, H. (2013) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000027 · Cited by 116
Parsons, C. G., Panchenko, V. A., Pinchenko, V. O., Tsyndrenko, A. Y., & Krishtal, O. A. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01228.x · Cited by 114
An open-label, flexible-dose study of memantine in major depressive disorder
Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180314ae7 · Cited by 113
Réus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F. P., Roesler, R., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.11.013 · Cited by 112
Salvadore, G., van der Veen, J. W. C., Zhang, Y., Marenco, S., Machado‐Vieira, R., Baumann, J., Ibrahim, L. A., Luckenbaugh, D. A., Shen, J., Drevets, W. C., et al. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001593 · Cited by 111
Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
Dravid, S. M., Burger, P. B., Prakash, A., Geballe, M. T., Yadav, R., Le, P., Vellano, K. M., Snyder, J. P., & Traynelis, S. F. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5390-09.2010 · Cited by 108
Actions of ?-cycloserine at the ? glycine receptor site in vivo
Emmett, M. R. (1991) · Neuropharmacology · doi:10.1016/0028-3908(91)90161-4 · Cited by 108
Zhang, X.-L., Sullivan, J. A., Moskal, J. R., & Stanton, P. K. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.018 · Cited by 107
Mealing, G. A. R., Lanthorn, T. H., Murray, C. L., Small, D. L., & Morley, P. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37943-1 · Cited by 103
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 102
Yoosefi, A., Sepehri, A. S., Kargar, M., Akhondzadeh, S., Sadeghi, M., Rafei, A., Alimadadi, A., & Ghaeli, P. (2013) · Journal of Ect · doi:10.1097/yct.0b013e3182a4b4c6 · Cited by 98
Mauskopf, J., Simon, G. E., Kalsekar, A., Nimsch, C. T., Dunayevich, E., & Cameron, A. E. (2008) · Depression and Anxiety · doi:10.1002/da.20505 · Cited by 98
Paul, R. H., Schaaff, N., Padberg, F., Möller, H., & Frodl, T. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701714370 · Cited by 98
Järventausta, K., Chrapek, W., Kampman, O., Tuohimaa, K., Björkqvist, M., Häkkinen, H., Yli‐Hankala, A., & Leinonen, E. V. J. (2013) · Journal of Ect · doi:10.1097/yct.0b013e318283b7e9 · Cited by 97
Robson, M. J., Elliott, M., Seminerio, M. J., & Matsumoto, R. R. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.002 · Cited by 95
Nishitani, N., Nagayasu, K., Asaoka, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000649 · Cited by 92
Moskal, J. R., Kuo, A. G., Weiss, C., Wood, P. L., Hanson, A. O., Kelso, S. R., Harris, R. B., & Disterhoft, J. F. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.006 · Cited by 91
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89
Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine
Chilukuri, H., Reddy, N. P., Pathapati, R. M., Manu, A. N., Jollu, S., & Shaik, A. B. (2014) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.127258 · Cited by 89
van Berckel, B. N. M. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00014-7 · Cited by 89
Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder
Duncan, W. C., Selter, J., Brutsche, N., Sarasso, S., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.042 · Cited by 86
Réus, G. Z., Abelaira, H. M., Stringari, R. B., Fries, G. R., Kapczinski, F. P., & Quevedo, J. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9281-2 · Cited by 83
Matsuoka, N., & Aigner, T. G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20677-2 · Cited by 82
Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82
Ketamine Causes Mitochondrial Dysfunction in Human Induced Pluripotent Stem Cell-Derived Neurons
Ito, H., Uchida, T., & Makita, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128445 · Cited by 81
Nations, K. R., Dogterom, P., Bursi, R., Schipper, J., Greenwald, S. D., Zraket, D., Gertsik, L., Johnstone, J., Lee, A. T. C., Pande, Y., et al. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458728 · Cited by 74
Li, Y., Zhu, Z. R., Ou, B. C., Wang, Y. Q., Tan, Z. B., Deng, C. M., Gao, Y., Tang, M., So, J. H., Mu, Y., et al. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.016 · Cited by 74
Correll, G. E., & Futter, G. E. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00101.x · Cited by 73
Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 73
Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression
Liebrenz, M., Stohler, R., & Borgeat, A. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701420481 · Cited by 73
Chindo, B. A., Adzu, B., Yahaya, T. A., & Gamaniel, K. S. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.04.018 · Cited by 71
Chronic Ketamine Administration Modulates Midbrain Dopamine System in Mice
Tan, S., Lam, W. P., Wai, M. S. M., Yu, W.-H. A., & Yew, D. T. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043947 · Cited by 70
Luckenbaugh, D. A., Ibrahim, L. A., Brutsché, N. E., Franco-Chaves, J. A., Mathews, D. C., Marquardt, C. A., Cassarly, C. N., & Zarate, C. A. (2012) · Bipolar Disorders · doi:10.1111/bdi.12003 · Cited by 69
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nürnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 69
Trujillo, K. A., Zamora, J. J., & Warmoth, K. P. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.014 · Cited by 68
Paslakis, G., Gilles, M., Meyer‐Lindenberg, A., & Deuschle, M. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1237375 · Cited by 66
Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series
Segmiller, F. M., Rüther, T., Linhardt, A., Padberg, F., Berger, M., Pogarell, O. M., Möller, H., Kohler, C., & Schüle, C. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.122 · Cited by 65
On the safety and benefits of repeated intravenous injections of ketamine for depression.
Blier, P., Zigman, D., & Blier, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.02.039 · Cited by 64
Goforth, H. W., & Holsinger, T. (2007) · Journal of Ect · doi:10.1097/01.yct.0000263257.44539.23 · Cited by 63
Szymkowicz, S. M., Finnegan, N., & Dale, R. M. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.015 · Cited by 62
Emnett, C. M., Eisenman, L. N., Taylor, A. M., Izumi, Y., Zorumski, C. F., & Mennerick, S. J. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.089334 · Cited by 62
Vale, S., Espejel, M. A., & Dominguez, J. C. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90153-x · Cited by 61
Intravenous Ketamine “Burst” for Refractory Depression in a Patient with Advanced Cancer
Stefanczyk-Sapieha, L., Oneschuk, D., & Demas, M. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2008.9828 · Cited by 61
Repeated Exposure to Anesthetic Ketamine Can Negatively Impact Neurodevelopment in Infants
Yan, J., Li, Y., Zhang, Y., Lu, Y., & Jiang, H. (2014) · Journal of Child Neurology · doi:10.1177/0883073813517508 · Cited by 61
The failure of the antidepressant drug discovery process is systemic
Hendrie, C. A., & Pickles, A. R. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112466185 · Cited by 60
Denk, M. C., Rewerts, C., Holsboer, F., Erhardt, A., & Turck, C. W. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010128 · Cited by 59
Rapid Response with Ketamine on Suicidal Cognition in Resistant Depression
Thakurta, R. G., Das, R., Bhattacharya, A., Saha, D., Sen, S., Singh, O. P., & Bisui, B. (2012) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.101793 · Cited by 58
Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial
Dietrich, D. E., Bode, L., Spannhuth, C. W., Lau, T., Huber, T. J., Brodhun, B., Ludwig, H., & Emrich, H. M. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.020110.x · Cited by 58
The psychotropic effects of cycloserine: A new use for an antibiotic
Crane, G. E. (1961) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(61)80007-2 · Cited by 57
The Use of a Series of Ketamine Infusions in Two Patients With Treatment-Resistant Depression
Messer, M., Haller, I. V., Larson, P. M., Pattison-Crisostomo, J., & Gessert, C. E. (2010) · Journal of Neuropsychiatry · doi:10.1176/jnp.2010.22.4.442 · Cited by 56
Niciu, M. J., Luckenbaugh, D. A., Ionescu, D. F., Richards, E. M., Voort, J. L. V., Ballard, E. D., Brutsché, N. E., Furey, M. L., & Zarate, C. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu039 · Cited by 56
Yang, C., Zhou, Z.-Q., Gao, Z.-Q., Shi, J.-Y., & Yang, J.-J. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.022 · Cited by 55
Extrasynaptic NMDA Receptor in Excitotoxicity
Zhou, X., Chen, Z., Yun, W., Ren, J., Li, C., & Wang, H. (2014) · The Neuroscientist · doi:10.1177/1073858414548724 · Cited by 45
The cardiovascular effects of ketamine in man
Johnstone, M. (1976) · Anaesthesia · doi:10.1111/j.1365-2044.1976.tb11898.x · Cited by 44
Fraga, D. B., Réus, G. Z., Abelaira, H. M., Luca, R. D. D., Canever, L., Pfaffenseller, B., Colpo, G. D., Kapczinski, F. P., Quevedo, J., & Zugno, A. I. (2013) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2012-0858 · Cited by 40
Wesseling, H., Rahmoune, H., Tricklebank, M. D., Guest, P. C., & Bahn, S. (2014) · Journal of Proteome Research · doi:10.1021/pr5009493 · Cited by 37
Skuza, G., & Rogóż, Z. (2006) · PubMed · Cited by 36
Majewski-Tiedeken, C. R., Rabin, C. R., & Siegel, S. J. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.08.009 · Cited by 35
Update on Partial Response in Depression
Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.01 · Cited by 34
Krystal, J. H., Petrakis, I. L., Limoncelli, D., Krasnicki, S., Trevisan, L. A., Pittman, B. P., & D’Souza, D. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.203 · Cited by 33
Poleszak, E., Wośko, S., Serefko, A., Szopa, A., Właź, A., Szewczyk, B., Nowak, G., & Właź, P. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.001 · Cited by 31
Young, S. N. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120128 · Cited by 31
Clinical and Functional Outcomes of Patients Who Experience Partial Response to Citalopram
Dennehy, E. B., Marangell, L. B., Martinez, J. M., Balasubramani, G. K., & Wisniewski, S. R. (2014) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000450317.76117.62 · Cited by 30
Extrasynaptic glutamate NMDA receptors: Key players in striatal function
Garcia-Munoz, M., López-Huerta, V. G., Carrillo‐Reid, L., & Arbuthnott, G. W. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.09.013 · Cited by 25
Brunson, K. L., Khanna, A., Cromwell, H. C., & Cohen, R. W. (2001) · Developmental Neuroscience · doi:10.1159/000048694 · Cited by 25
Nations, K. R., Bursi, R., Dogterom, P., Ereshefsky, L., Gertsik, L., Mant, T., & Schipper, J. (2012) · Drugs in R&D · doi:10.2165/11634360-000000000-00000 · Cited by 23
Farha, K. A., Bruggeman, R., & Baljé-Volkers, C. P. (2014) · ISRN Psychiatry · doi:10.1155/2014/652750 · Cited by 23
Proceed with Caution: Off-label Ketamine Treatment for Major Depressive Disorder
Sisti, D. A., Segal, A. G., & Thase, M. E. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0527-z · Cited by 21
Becker, A., Grecksch, G., Schwegler, H., & Roskoden, T. (2008) · Medicinal Chemistry · doi:10.2174/157340608784325124 · Cited by 21
Steciuk, M., Kram, M., Kramer, G. L., & Petty, F. (2000) · Stress · doi:10.3109/10253890009001123 · Cited by 18
Soriano, S. G. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31825ae442 · Cited by 18
NIMH-Funded Pragmatic Trials: Moving On
Wang, P. S., & Insel, T. R. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.161 · Cited by 16
Mori, T., Yoshizawa, K., Shibasaki, M., & Suzuki, T. (2012) · Journal of Pharmacological Sciences · doi:10.1254/jphs.12r08cp · Cited by 14
Zuo, D., Wang, C., Li, Z., Lin, L., Duan, Z., Qi, H., Li, L., Sun, F., & Wu, Y. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.06.002 · Cited by 13
Yonezawa, Y., Hondo, H., Hashimoto, K., Matsumoto, T., Hirano, M., Uchimura, H., & Kuroki, T. (1993) · Journal of Neural Transmission · doi:10.1007/bf01277028 · Cited by 9
Vamvakides, A. (1998) · PubMed · Cited by 6
Pipeline for New Antidepressants Flowing Slowly
Yan, J. (2012) · Psychiatric News · doi:10.1176/pn.47.5.psychnews_47_5_1-b · Cited by 4
No new meds: With drug firms in retreat, the pipeline for new psychiatric medications dries up
Sanders, L. (2013) · Science News · doi:10.1002/scin.5591830422 · Cited by 3
The Ketamine Challenge: When Practice Leaps Ahead of Science
Lieberman, J. A. (2015) · Psychiatric News · doi:10.1176/appi.pn.2015.2a26 · Cited by 1
Research works printed but not linked: 6
Cited by
Sorted by citations
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Metadata
- Authors
- Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments
- Affiliations
- University of Miami (US)
- University of Iowa (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2015-10-01
- Volume
- 172
- Issue
- 10
- Pages
- 950-966
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2111728433
- Semantic Scholar
- 1554f1974f06fcabaaf6be07d58e1ebf23572172
- Cited by
- 598
- References
- 177
- Citations by year
- 2026: 27 · 2025: 36 · 2024: 37 · 2023: 50 · 2022: 53 · 2021: 65 · 2020: 62 · 2019: 65 · 2018: 71 · 2017: 64 · 2016: 62 · 2015: 5
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Foundation for Suicide Prevention
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Brown University
- Celgene
- University of Miami
- Emory University
- Sunovion
- National Alliance for Research on Schizophrenia and Depression
- OPKO Health
- University of Oxford
- Mitsubishi Tanabe Pharma Corporation
- H. Lundbeck A/S
- National Institutes of Health
- Health Resources and Services Administration
- School of Medicine, Emory University
- Allergan
- Leonard M. Miller School of Medicine
- Roy J. and Lucille A. Carver College of Medicine, University of Iowa
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, NMDA receptor antagonists, major depressive disorder, antidepressant efficacy, rapid-acting antidepressants, D-cycloserine, psychotomimetic effects, dissociative effects, glutamate modulation, treatment response, remission
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
